About

Terray Therapeutics focuses on discovering and developing small molecule drugs using a combination of experimental and computational methods. The company generates a large dataset of over two billion unique target-ligand binding measurements, adding 150 million new measurements each month. This extensive data allows for precise predictions of molecular properties through deep learning models. Terray employs a fast design-make-test-analyze cycle, completing each cycle in under a month, which enables the exploration of chemical space and the identification of effective small molecules for various targets. While the primary focus is on immunology, Terray collaborates with pharmaceutical and biotech companies to tackle a wide range of therapeutic challenges, creating additional revenue streams alongside its internal drug discovery initiatives.

Simplify's Take

What believers are saying

• Terray raised $120M in Series B funding, boosting financial stability.
• Partnership with Bristol Myers Squibb enhances resource access and expertise.
• Investment from NVIDIA supports AI-driven drug design advancements.

What critics are saying

• Competition from AI-driven biotech firms like Insilico Medicine is increasing.
• Technological advancements may outpace Terray's current capabilities.
• Dependence on partnerships could be risky if collaborations fail.

What makes Terray Therapeutics unique

• Terray integrates AI and wet lab science for efficient drug discovery.
• Their platform generates over 150 million new measurements monthly, enhancing data precision.
• Terray's rapid cycle allows exploration of millions of molecules in under a month.

Help us improve and share your feedback! Did you find this helpful?

YesNo